Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Hopfinger, G; Nösslinger, T; Lang, A; Linkesch, W; Melchardt, T; Weiss, L; Egle, A; Greil, R.
Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Ann Hematol. 2014; 93(3):459-462
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Linkesch Werner
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Given the poor outcome of relapsed and refractory peripheral T cell lymphoma (PTCL), we explored a combination of lenalidomide, vorinostat, and dexamethasone to test the feasibility of this therapy in relapsed and refractory PTCL. Eight patients were accrued: two peripheral T cell lymphoma, unspecified; five angioimmunoblastic T cell lymphoma; and one ALK-negative anaplastic large-cell lymphoma. A dose escalation of lenalidomide (days 1-21, q28) was planned using a 3 + 3 design. As two patients treated with 10 mg/day experienced dose-limiting toxicity (thrombocytopenia grade 3, stroke grade 4), the primary end point of our trial was reached; the maximal tolerable dose of lenalidomide was 5 mg/day (level -I). Adverse events grade ≥3 were observed as thrombocytopenia (23 %), leukocytopenia (15 %), anemia (8 %), and neutropenia (8 %). One complete remission (10.3 months), one partial remission (11.3 months), one stable disease (11.9 months), and four progressive disease (overall response rate 25 %) were observed. The median progression-free survival was 2.2 months and the median OS was 6.7 months. In conclusion, the poor results obtained with lenalidomide in combination with vorinostat and dexamethasone provide no arguments that could justify further investigation of this drug combination for the treatment of relapsed PTCL.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Angiogenesis Inhibitors - administration & dosage
Angiogenesis Inhibitors - therapeutic use
Antineoplastic Agents, Hormonal - administration & dosage
Antineoplastic Agents, Hormonal - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cohort Studies -
Dexamethasone - administration & dosage
Dexamethasone - therapeutic use
Drug Resistance, Neoplasm -
Feasibility Studies -
Female -
Histone Deacetylase Inhibitors - administration & dosage
Histone Deacetylase Inhibitors - therapeutic use
Humans -
Hydroxamic Acids - administration & dosage
Hydroxamic Acids - therapeutic use
Lenalidomide -
Lymphoma, Large-Cell, Anaplastic - drug therapy
Lymphoma, Large-Cell, Anaplastic - pathology
Lymphoma, Large-Cell, Immunoblastic - drug therapy
Lymphoma, Large-Cell, Immunoblastic - pathology
Lymphoma, T-Cell, Peripheral - drug therapy
Lymphoma, T-Cell, Peripheral - pathology
Male -
Middle Aged -
Neoplasm Staging -
Recurrence -
Survival Analysis -
Thalidomide - administration & dosage
Thalidomide - analogs & derivatives
Thalidomide - therapeutic use
Thrombocytopenia - chemically induced
Vorinostat -

Find related publications in this database (Keywords)
Peripheral T cell lymphoma
PTCL
Lenalidomide
Vorinostat
© Meduni Graz Impressum